Electronic products manufacturer AMETEK (NYSE: AME) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 15% year on year to $2.04 billion. Its non-GAAP profit of $2.09 per share was 4.8% above analysts’ consensus estimates.

Is now the time to buy AME? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

AMETEK’s second quarter results were met with a positive market response, driven by broad-based demand across multiple end markets, particularly in semiconductor, aerospace, and MedTech applications. Management emphasized that robust organic growth, supported by recent acquisitions and high order volumes, contributed significantly to overall performance. CEO David Zapico noted that the company’s ability to deliver “double-digit organic sales growth” and a record backlog was supported by strong execution and effective working capital management. The company’s Electronic Instruments Group benefited from process instrumentation and power solutions, while the Electromechanical Group saw notable contributions from MedTech and automation businesses.

Looking ahead, AMETEK’s raised full-year guidance is anchored in ongoing infrastructure investments across AI, defense, and power grid modernization. Management stated that demand drivers such as AI-fueled semiconductor complexity, global defense spending, and expanding automation will support continued momentum. Zapico highlighted that the acquisition pipeline remains robust, with the pending Indicor Instrumentation deal expected to further strengthen AMETEK’s position. He added, “We are supplying mission-critical essential products for new semiconductor fabs, new power plants, and defense modernization,” pointing to durable growth themes for the remainder of the year.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to accelerating orders growth, expanding product innovation, and targeted acquisitions that enhanced segment diversity.

• Orders surge across segments: Orders rose sharply, with organic orders up 25%, reflecting strong project activity in process instrumentation, semiconductor, aerospace, and power grid businesses. Management described the order momentum as “exceptional,” with June marking a record for monthly orders.

• Backlog and visibility improve: The company’s backlog reached $4.11 billion, providing greater visibility into future revenue. Management indicated that roughly 80% of the backlog is expected to ship in the next 12 months, with both short-cycle and longer-cycle project portfolios filling in for 2027.

• Paragon Medical and MedTech strength: Paragon Medical, within the Electromechanical Group, delivered outsized growth due to new product wins in orthopedics and drug delivery, exemplifying how AMETEK leverages downturns for integration and subsequent margin expansion.

• AI and semiconductor demand: The Electronic Instruments Group saw growth from AI-driven investment in semiconductor manufacturing, where advanced optics and metrology solutions are in high demand. The Zygo business, in particular, benefited from increased complexity in semiconductor fabrication.

• Acquisition pipeline and integration: Management reiterated that strategic M&A remains a priority, with the pending Indicor Instrumentation acquisition expected to bring differentiated technology and high recurring revenue. The integration of recent deals, such as FARO, is on plan and anticipated to contribute to core margin expansion in the coming quarters.

Drivers of Future Performance

AMETEK’s outlook for the year is shaped by persistent demand in infrastructure and technology end markets, with margin expansion supported by ongoing productivity initiatives and integration of new acquisitions.

• Infrastructure and secular demand: Management expects investment cycles in AI infrastructure, defense modernization, and power grid upgrades to continue driving demand for the company’s mission-critical products. These long-term trends are seen as providing durability and multi-year growth opportunities.

• Margin expansion from integration: The integration of Paragon Medical and FARO, along with productivity programs, is forecast to improve operating margins. Management pointed to enhanced engineering and product vitality—new products accounted for 25% of revenue—as contributors to future margin gains.

• Acquisition execution risk: While the acquisition pipeline remains robust, management acknowledged that successful integration and realization of expected cost synergies, particularly with Indicor, are essential for sustaining profitability. Any delays or challenges in these areas may introduce risk to the company’s margin trajectory.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will monitor (1) the pace of order conversion to revenue and any shifts in backlog realization, (2) the successful integration and margin contribution from acquisitions including Indicor and FARO, and (3) continued demand strength in end markets such as AI-driven semiconductors, aerospace, and MedTech. Execution on product innovation and productivity targets will also be closely watched.

AMETEK currently trades at $254.58, up from $243.77 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.